Patents by Inventor Kurt Vogel

Kurt Vogel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8642256
    Abstract: Compositions, including antibodies, polypeptides, and organic molecules, kits, and methods for probing molecular interactions (e.g., deubiquination, ubiquination and kinase activity), e.g., using resonance energy transfer (RET) are provided.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: February 4, 2014
    Assignee: Life Technologies Corporation
    Inventors: Kurt Vogel, Steven Riddle, Robert Horton, Matthew Robers, Gregory Michaud, Thomas Machleidt, Kevin Vedvik, Kristin Huwiler
  • Publication number: 20130243903
    Abstract: The present invention relates to an acidic ready to drink beverage having a water activity greater than 0.95, a pH value lower than 6, and enriched with an active phytase enzyme.
    Type: Application
    Filed: August 19, 2011
    Publication date: September 19, 2013
    Applicant: DSM IP ASSETS B.V.
    Inventors: Gabriela Badolato Bönisch, Robert Beudeker, Sylvia P. Poulos, Loni Schweikert, Kurt Vogel, Karin Wertz
  • Patent number: 8409814
    Abstract: The present invention relates to biosensors. In some embodiments, the biosensors are modified ligand binding molecules. In some embodiments, the modified ligand binding molecule is a phosphate binding protein (PBP). In some embodiments, the modified ligand binding molecules are labeled to be capable of RET, e.g., comprising a donor and acceptor moiety. In some embodiments of the invention, there is a detectable change in RET (e.g., FRET) when the modified ligand binding molecule binds and/or releases the ligand (e.g., phosphate). The invention also provides related methods, reactions and assays.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: April 2, 2013
    Assignee: Life Technologies Corporation
    Inventors: Kurt Vogel, Rhonda Newman, Steven Riddle
  • Publication number: 20120231541
    Abstract: Disclosed are assays, methods, and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. In particular, whether a test compound has the effect to prolong the Q-T interval as measured by an electrocardiogram in a human. The assays, methods, and kits disclosed herein make use of the binding interaction between novel fluorescent tracers and the hERG K+ channel, and the propensity of a test compound to influence that binding interaction.
    Type: Application
    Filed: March 9, 2012
    Publication date: September 13, 2012
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: David Piper, Stephen Hess, Mohammed Saleh Shekhani, Thomas Livelli, Zhong Zhong, Steve Duff, Kurt Vogel
  • Patent number: 8133695
    Abstract: Disclosed are assays, methods, and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. In particular, whether a test compound has the effect to prolong the Q-T interval as measured by an electrocardiogram in a human. The assays, methods, and kits disclosed herein make use of the binding interaction between novel fluorescent tracers and the hERG K+ channel, and the propensity of a test compound to influence that binding interaction.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: March 13, 2012
    Assignee: Life Technologies Corporation
    Inventors: David Piper, Kurt Vogel, Mohammed Saleh Shekhani, Stephen Hess, Steve Duff, Thomas Livelli, Zhong Zhong
  • Publication number: 20110111422
    Abstract: The present invention relates to biosensors. In some embodiments, the biosensors are modified ligand binding molecules. In some embodiments, the modified ligand binding molecule is a phosphate binding protein (PBP). In some embodiments, the modified ligand binding molecules are labeled to be capable of RET, e.g., comprising a donor and acceptor moiety. In some embodiments of the invention, there is a detectable change in RET (e.g., FRET) when the modified ligand binding molecule binds and/or releases the ligand (e.g., phosphate). The invention also provides related methods, reactions and assays.
    Type: Application
    Filed: September 1, 2010
    Publication date: May 12, 2011
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Kurt VOGEL, Rhonda Newman, Steven Riddle
  • Publication number: 20090298123
    Abstract: New lipase enzymes (both nucleic acids and polypeptides) are provided. Compositions which include these polypeptides, proteins, nucleic acids, recombinant cells, as well as methods involving the enzymes, antibodies to the enzymes, and methods of using the enzymes are also provided.
    Type: Application
    Filed: August 1, 2008
    Publication date: December 3, 2009
    Applicant: Codexis, Inc.
    Inventors: Lorraine J. Giver, Jeremy Minshull, Kurt Vogel
  • Patent number: 7619059
    Abstract: Compositions, methods, and kits for detecting and monitoring post-translational modification activities, including kinase or phosphatase activities, are described. The compositions typically include a peptide, a first detectable moiety, a first binding member, and a protease cleavage site. Modification of a composition by a post-translational modification enzyme, such as a kinase or phosphatase, alters the proteolytic sensitivity of the peptide, resulting in a change of a detectable property of the composition when it is associated noncovalently with a probe composition that includes a second binding member and a second detectable moiety. Panel assays for determining substrates or modulators of enzymatic activities are also described.
    Type: Grant
    Filed: September 9, 2004
    Date of Patent: November 17, 2009
    Assignee: Life Technologies Corporation
    Inventors: Kevin R. Kupcho, Kurt Vogel, Elizabeth A. Werner, Jane A. Beebe, Tony A. Klink, David A. Lasky, Karen M. Kleman-Leyer, Richard Somberg
  • Publication number: 20090253148
    Abstract: Disclosed are assays, methods, and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. In particular, whether a test compound has the effect to prolong the Q-T interval as measured by an electrocardiogram in a human. The assays, methods, and kits disclosed herein make use of the binding interaction between novel fluorescent tracers and the hERG K+ channel, and the propensity of a test compound to influence that binding interaction.
    Type: Application
    Filed: February 27, 2009
    Publication date: October 8, 2009
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: David Piper, Stephen Hess, Mohammed Saleh Shekhani, Thomas Livelli, Zhong Zhong, Steve Duff, Kurt Vogel
  • Publication number: 20080220118
    Abstract: The present invention relates to phytase variants, their preparation and uses, which phytase variants, when aligned according to FIG. 1, are amended as compared to a model phytase in at least one of a number of positions. Preferred model phytases are basidiomycete and ascomycete phytases, such as Peniophora phytase and Aspergillus phytases. Preferred phytase variants exhibits amended activity characteristics, such as improved specific activity and/or improved thermostability.
    Type: Application
    Filed: November 19, 2007
    Publication date: September 11, 2008
    Applicant: Novozymes A/S
    Inventors: Allan Svendsen, Soren Flensted Lassen, Dirk Kostrewa, Luis Pasamontes, Martin Lehman, Andrea Tomschy, Adolphus Van Loon, Kurt Vogel, Markus Wyss
  • Publication number: 20080219965
    Abstract: The present invention relates to phytase variants, their preparation and uses, which phytase variants, when aligned according to FIG. 1, are amended as compared to a model phytase in at least one of a number of positions. Preferred model phytases are basidiomycete and ascomycete phytases, such as Peniophora phytase and Aspergillus phytases. Preferred phytase variants exhibits amended activity characteristics, such as improved specific activity and/or improved thermostability.
    Type: Application
    Filed: November 19, 2007
    Publication date: September 11, 2008
    Applicant: Novozymes A/S
    Inventors: Allan Svendsen, Soren Flensted Lassen, Dirk Kostrewa, Luis Pasamontes, Martin Lehmann, Andrea Tomschy, Adolphus Van Loon, Kurt Vogel, Markus Wyss
  • Publication number: 20080213811
    Abstract: The present invention relates to biosensors. In some embodiments, the biosensors are modified ligand binding molecules. In some embodiments, the modified ligand binding molecule is a phosphate binding protein (PBP). In some embodiments, the modified ligand binding molecules are labeled to be capable of RET, e.g., comprising a donor and acceptor moiety. In some embodiments of the invention, there is a detectable change in RET (e.g., FRET) when the modified ligand binding molecule binds and/or releases the ligand (e.g., phosphate). The invention also provides related methods, reactions and assays.
    Type: Application
    Filed: August 10, 2007
    Publication date: September 4, 2008
    Applicant: Invitrogen Corporation
    Inventors: Kurt Vogel, Rhonda Newman, Steven Riddle
  • Patent number: 7407786
    Abstract: New lipase enzymes (both nucleic acids and polypeptides) are provided. Compositions which include these polypeptides, proteins, nucleic acids, recombinant cells, as well as methods involving the enzymes, antibodies to the enzymes, and methods of using the enzymes are also provided.
    Type: Grant
    Filed: August 17, 2004
    Date of Patent: August 5, 2008
    Assignee: Codexis, Inc.
    Inventors: Lorraine J. Giver, Jeremy Minshull, Kurt Vogel
  • Publication number: 20080138836
    Abstract: Compositions, including antibodies, polypeptides, and organic molecules, kits, and methods for probing molecular interactions (e.g., deubiquination, ubiquination and kinase activity) using resonance energy transfer (RET) are provided.
    Type: Application
    Filed: July 20, 2007
    Publication date: June 12, 2008
    Applicant: INVITROGEN CORPORATION
    Inventors: Gregory Michaud, Kurt Vogel, Matthew Robers, Robert Horton, Steven Riddle
  • Patent number: 7326554
    Abstract: The present invention relates to phytase variants, their preparation and uses, which phytase variants, when aligned according to FIG. 1, are amended as compared to a model phytase in at least one of a number of positions. Preferred model phytases are basidiomycete and ascomycete phytases, such as Peniophora phytase and Aspergillus phytases. Preferred phytase variants exhibits amended activity characteristics, such as improved specific activity and/or improved thermostability.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: February 5, 2008
    Assignee: Novozymes Als
    Inventors: Allan Svendsen, Soren Flensted Lassen, Dirk Kostrewa, Luis Pasamontes, Martin Lehman, Andrea Tomschy, Adolphus Van Loon, Kurt Vogel, Markus Wyss
  • Publication number: 20070264678
    Abstract: Compositions, including antibodies, polypeptides, and organic molecules, kits, and methods for probing molecular interactions (e.g., deubiquination, ubiquination and kinase activity), e.g., using resonance energy transfer (RET) are provided.
    Type: Application
    Filed: October 30, 2006
    Publication date: November 15, 2007
    Applicant: INVITROGEN CORPORATION
    Inventors: Kurt VOGEL, Steven RIDDLE, Robert HORTON, Matthew ROBERS, Gregory MICHAUD, Thomas MACHLEIDT, Kevin VEDVIK, Kristin HUWILER
  • Publication number: 20060245456
    Abstract: Systems, methods, circuits and/or devices for generating high repetition rate ultra-short pulses are described. As one of many examples, an optical pulse generating laser system is described that produces mode-locked optical pulses. The laser system incorporates an optical pulse generation device that includes two optical loops coupled via a beam splitter. In addition, the optical pulse generation device includes an optical gain medium that is associated with the first optical loop, and a saturable element that is disposed in either the first optical loop or the second optical loop. The saturable element is operable to modulate a group of optical pulses propagating in at least one of the first optical loop and the second optical loop to create a group of substantially regular modulated pulses.
    Type: Application
    Filed: October 4, 2005
    Publication date: November 2, 2006
    Applicant: Precision Photonics Corporation
    Inventors: Jacob Lasri, Kurt Vogel, Neil Claussen, Christopher Myatt
  • Patent number: 7078183
    Abstract: A process for the production of a modified phytase with a desired property improved over the property of the corresponding unmodified phytase is disclosed, as well as modified phytases, polynucleotides encoding modified phytases, and animal feed including modified phytases.
    Type: Grant
    Filed: February 11, 2004
    Date of Patent: July 18, 2006
    Assignee: DSM IP Assets B.V.
    Inventors: Dirk Kostrewa, Luis Pasamontes, Andrea Tomschy, Adolphus van Loon, Kurt Vogel, Markus Wyss
  • Publication number: 20050214919
    Abstract: New lipase enzymes (both nucleic acids and polypeptides) are provided. Compositions which include these polypeptides, proteins, nucleic acids, recombinant cells, as well as methods involving the enzymes, antibodies to the enzymes, and methods of using the enzymes are also provided.
    Type: Application
    Filed: August 17, 2004
    Publication date: September 29, 2005
    Inventors: Lorraine Giver, Jeremy Minshull, Kurt Vogel
  • Publication number: 20050209146
    Abstract: Bifunctional molecules and methods for their use in the production of binary complexes in a host are provided. The bifunctional molecule is a conjugate of a drug moiety and a presenter protein ligand. In the subject methods, an effective amount of the bifunctional molecule is administered to the host. The bifunctional molecule binds to the presenter protein to produce a binary complex that exhibits at least one of improved affinity, specificity or selectivity as compared to the corresponding free drug. The subject methods and compositions find use in a variety of therapeutic applications.
    Type: Application
    Filed: December 13, 2004
    Publication date: September 22, 2005
    Inventors: Roger Briesewitz, Gerald Crabtree, Thomas Wandless, Gregory Ray, Kurt Vogel